Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive neoplasm 
clinically characterized by sudden onset of constitutional symptoms, 
lymphadenopathy, hepatosplenomegaly, frequent autoimmune phenomena, particularly 
hemolytic anemia and thrombocytopenia, and polyclonal hypergammaglobulinemia. 
The lymph node histological picture is also distinctive, constituted by a 
polymorphic infiltrate, a marked proliferation of high endothelial venules, and 
a dense meshwork of dentritic cells. The neoplastic CD4+ T-cells represent a 
minority of the lymph node cell population; its detection is facilitated by the 
aberrant expression of CD10. Almost all cases arbor an EBV infected B-cell 
population. Patients with AITL have a poor prognosis with conventional 
treatment, with a median overall survival of less than 3 years. Patients 
achieving a good clinical response seem beneficiate from a consolidation with 
high-dose therapy and autologous stem cell transplantation. Constitutional 
symptoms and autoimmune phenomena, and some times also the neoplastic masses may 
respond to immunosuppressive or immunomodulatory agents such as thalidomide.